Table 3.

Effect of high advanced glycation end product levels on the non-alcoholic fatty liver disease-associated steatosis severity

Variable	SE	OR (95%CI)	Sensitivity	Specificity	Accuracy
Crude model	0.47	2.64 (1.04-6.92)	0.62	0.61	0.61
Model 1	0.52	3.38 (1.24-9.98)	0.60	0.73	0.64
Model 2	0.55	3.34 (1.17-10.40)	0.71	0.68	0.69
Model 3	0.61	4.52 (1.44-16.28)	0.78	0.72	0.75
Model 4	0.62	4.66 (1.45-17.16)	0.77	0.77	0.77

Model 1: Adjusted for gender; Model 2: Additionally adjusted for gamma-glutamyl transferase; Model 3: Additionally adjusted for altered blood glucose (categorical ≥ 126, 110 ≤ 125); Model 4: Additionally adjusted for high cholesterol. High cholesterol was defined as use of medication to treat dyslipidemia or low-density lipoprotein cholesterol ≥ 130. OR: Odds ratio; CI: Confidence interval.